This matters for Australia because it provides the first real-world signal that medicines may be able to bend the obesity curve at scale. This is something that decades of lifestyle-only interventions have failed to achieve. Yet, despite this promise, access in Australia remains confined to those who can pay privately.
Obesity medicines, the limits of the PBS, and the test of policy imagination
January 28, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News
